Eintrag weiter verarbeiten
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir
Gespeichert in:
| Zeitschriftentitel: | Journal of Viral Hepatitis |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , |
| In: | Journal of Viral Hepatitis, 24, 2017, 2, S. 148-154 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Xu, J.‐H. Song, L.‐W. Li, N. Wang, S. Zeng, Z. Si, C.‐W. Li, J. Mao, Q. Zhang, D.‐Z. Tang, H. Sheng, J.‐F. Chen, X.‐Y. Ning, Q. Shi, G.‐F. Xie, Q. Yuan, Q. Yu, Y.‐Y. Xia, N.‐S. Xu, J.‐H. Song, L.‐W. Li, N. Wang, S. Zeng, Z. Si, C.‐W. Li, J. Mao, Q. Zhang, D.‐Z. Tang, H. Sheng, J.‐F. Chen, X.‐Y. Ning, Q. Shi, G.‐F. Xie, Q. Yuan, Q. Yu, Y.‐Y. Xia, N.‐S. |
|---|---|
| author |
Xu, J.‐H. Song, L.‐W. Li, N. Wang, S. Zeng, Z. Si, C.‐W. Li, J. Mao, Q. Zhang, D.‐Z. Tang, H. Sheng, J.‐F. Chen, X.‐Y. Ning, Q. Shi, G.‐F. Xie, Q. Yuan, Q. Yu, Y.‐Y. Xia, N.‐S. |
| spellingShingle |
Xu, J.‐H. Song, L.‐W. Li, N. Wang, S. Zeng, Z. Si, C.‐W. Li, J. Mao, Q. Zhang, D.‐Z. Tang, H. Sheng, J.‐F. Chen, X.‐Y. Ning, Q. Shi, G.‐F. Xie, Q. Yuan, Q. Yu, Y.‐Y. Xia, N.‐S. Journal of Viral Hepatitis Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir Virology Infectious Diseases Hepatology |
| author_sort |
xu, j.‐h. |
| spelling |
Xu, J.‐H. Song, L.‐W. Li, N. Wang, S. Zeng, Z. Si, C.‐W. Li, J. Mao, Q. Zhang, D.‐Z. Tang, H. Sheng, J.‐F. Chen, X.‐Y. Ning, Q. Shi, G.‐F. Xie, Q. Yuan, Q. Yu, Y.‐Y. Xia, N.‐S. 1352-0504 1365-2893 Wiley Virology Infectious Diseases Hepatology http://dx.doi.org/10.1111/jvh.12626 <jats:title>Summary</jats:title><jats:p>Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (<jats:italic>P</jats:italic><.01). We defined 4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup>, with a maximum sum of sensitivity and specificity, as the optimal cut‐off value of baseline anti‐HBc level to predict seroconversion. Patients with baseline anti‐HBc ≥4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup> had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti‐HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05‐16.34, <jats:italic>P</jats:italic>=.001). The baseline anti‐HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17‐13.25, <jats:italic>P</jats:italic><.001). Hence, baseline anti‐HBc titre is a useful predictor of long‐term entecavir therapy efficacy in HBeAg‐positive CHB patients, which could be used to optimize antiviral therapy.</jats:p> Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir Journal of Viral Hepatitis |
| doi_str_mv |
10.1111/jvh.12626 |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmguMTI2MjY |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmguMTI2MjY |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2017 |
| imprint_str_mv |
Wiley, 2017 |
| issn |
1352-0504 1365-2893 |
| issn_str_mv |
1352-0504 1365-2893 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
xu2017baselinehepatitisbcoreantibodypredictstreatmentresponseinchronichepatitisbpatientsreceivinglongtermentecavir |
| publishDateSort |
2017 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Viral Hepatitis |
| source_id |
49 |
| title |
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_unstemmed |
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_full |
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_fullStr |
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_full_unstemmed |
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_short |
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_sort |
baseline hepatitis b core antibody predicts treatment response in chronic hepatitis b patients receiving long‐term entecavir |
| topic |
Virology Infectious Diseases Hepatology |
| url |
http://dx.doi.org/10.1111/jvh.12626 |
| publishDate |
2017 |
| physical |
148-154 |
| description |
<jats:title>Summary</jats:title><jats:p>Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (<jats:italic>P</jats:italic><.01). We defined 4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup>, with a maximum sum of sensitivity and specificity, as the optimal cut‐off value of baseline anti‐HBc level to predict seroconversion. Patients with baseline anti‐HBc ≥4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup> had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti‐HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05‐16.34, <jats:italic>P</jats:italic>=.001). The baseline anti‐HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17‐13.25, <jats:italic>P</jats:italic><.001). Hence, baseline anti‐HBc titre is a useful predictor of long‐term entecavir therapy efficacy in HBeAg‐positive CHB patients, which could be used to optimize antiviral therapy.</jats:p> |
| container_issue |
2 |
| container_start_page |
148 |
| container_title |
Journal of Viral Hepatitis |
| container_volume |
24 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792345571436003329 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:24:26.058Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Baseline+hepatitis+B+core+antibody+predicts+treatment+response+in+chronic+hepatitis+B+patients+receiving+long%E2%80%90term+entecavir&rft.date=2017-02-01&genre=article&issn=1365-2893&volume=24&issue=2&spage=148&epage=154&pages=148-154&jtitle=Journal+of+Viral+Hepatitis&atitle=Baseline+hepatitis+B+core+antibody+predicts+treatment+response+in+chronic+hepatitis+B+patients+receiving+long%E2%80%90term+entecavir&aulast=Xia&aufirst=N.%E2%80%90S.&rft_id=info%3Adoi%2F10.1111%2Fjvh.12626&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792345571436003329 |
| author | Xu, J.‐H., Song, L.‐W., Li, N., Wang, S., Zeng, Z., Si, C.‐W., Li, J., Mao, Q., Zhang, D.‐Z., Tang, H., Sheng, J.‐F., Chen, X.‐Y., Ning, Q., Shi, G.‐F., Xie, Q., Yuan, Q., Yu, Y.‐Y., Xia, N.‐S. |
| author_facet | Xu, J.‐H., Song, L.‐W., Li, N., Wang, S., Zeng, Z., Si, C.‐W., Li, J., Mao, Q., Zhang, D.‐Z., Tang, H., Sheng, J.‐F., Chen, X.‐Y., Ning, Q., Shi, G.‐F., Xie, Q., Yuan, Q., Yu, Y.‐Y., Xia, N.‐S., Xu, J.‐H., Song, L.‐W., Li, N., Wang, S., Zeng, Z., Si, C.‐W., Li, J., Mao, Q., Zhang, D.‐Z., Tang, H., Sheng, J.‐F., Chen, X.‐Y., Ning, Q., Shi, G.‐F., Xie, Q., Yuan, Q., Yu, Y.‐Y., Xia, N.‐S. |
| author_sort | xu, j.‐h. |
| container_issue | 2 |
| container_start_page | 148 |
| container_title | Journal of Viral Hepatitis |
| container_volume | 24 |
| description | <jats:title>Summary</jats:title><jats:p>Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (<jats:italic>P</jats:italic><.01). We defined 4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup>, with a maximum sum of sensitivity and specificity, as the optimal cut‐off value of baseline anti‐HBc level to predict seroconversion. Patients with baseline anti‐HBc ≥4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup> had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti‐HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05‐16.34, <jats:italic>P</jats:italic>=.001). The baseline anti‐HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17‐13.25, <jats:italic>P</jats:italic><.001). Hence, baseline anti‐HBc titre is a useful predictor of long‐term entecavir therapy efficacy in HBeAg‐positive CHB patients, which could be used to optimize antiviral therapy.</jats:p> |
| doi_str_mv | 10.1111/jvh.12626 |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmguMTI2MjY |
| imprint | Wiley, 2017 |
| imprint_str_mv | Wiley, 2017 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1352-0504, 1365-2893 |
| issn_str_mv | 1352-0504, 1365-2893 |
| language | English |
| last_indexed | 2024-03-01T17:24:26.058Z |
| match_str | xu2017baselinehepatitisbcoreantibodypredictstreatmentresponseinchronichepatitisbpatientsreceivinglongtermentecavir |
| mega_collection | Wiley (CrossRef) |
| physical | 148-154 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Journal of Viral Hepatitis |
| source_id | 49 |
| spelling | Xu, J.‐H. Song, L.‐W. Li, N. Wang, S. Zeng, Z. Si, C.‐W. Li, J. Mao, Q. Zhang, D.‐Z. Tang, H. Sheng, J.‐F. Chen, X.‐Y. Ning, Q. Shi, G.‐F. Xie, Q. Yuan, Q. Yu, Y.‐Y. Xia, N.‐S. 1352-0504 1365-2893 Wiley Virology Infectious Diseases Hepatology http://dx.doi.org/10.1111/jvh.12626 <jats:title>Summary</jats:title><jats:p>Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (<jats:italic>P</jats:italic><.01). We defined 4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup>, with a maximum sum of sensitivity and specificity, as the optimal cut‐off value of baseline anti‐HBc level to predict seroconversion. Patients with baseline anti‐HBc ≥4.65 log<jats:sub>10</jats:sub> IU·mL<jats:sup>−1</jats:sup> had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti‐HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05‐16.34, <jats:italic>P</jats:italic>=.001). The baseline anti‐HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17‐13.25, <jats:italic>P</jats:italic><.001). Hence, baseline anti‐HBc titre is a useful predictor of long‐term entecavir therapy efficacy in HBeAg‐positive CHB patients, which could be used to optimize antiviral therapy.</jats:p> Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir Journal of Viral Hepatitis |
| spellingShingle | Xu, J.‐H., Song, L.‐W., Li, N., Wang, S., Zeng, Z., Si, C.‐W., Li, J., Mao, Q., Zhang, D.‐Z., Tang, H., Sheng, J.‐F., Chen, X.‐Y., Ning, Q., Shi, G.‐F., Xie, Q., Yuan, Q., Yu, Y.‐Y., Xia, N.‐S., Journal of Viral Hepatitis, Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir, Virology, Infectious Diseases, Hepatology |
| title | Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_full | Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_fullStr | Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_full_unstemmed | Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_short | Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| title_sort | baseline hepatitis b core antibody predicts treatment response in chronic hepatitis b patients receiving long‐term entecavir |
| title_unstemmed | Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| topic | Virology, Infectious Diseases, Hepatology |
| url | http://dx.doi.org/10.1111/jvh.12626 |